An update on clinical and pharmacological aspects of drug-eluting stents

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 6, Issue 4, 2006, Pages 245-255

  Anis, Rafik R ^a   Karsch, Karl R ^a   Oberhoff, Martin ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Anti Inflammatory; Immunomodular; In Stent Restenosis; Paclitaxel; Polymer Coating; SIRIUS trial

Indexed keywords

ABT 578; ACETYLSALICYLIC ACID; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; BATIMASTAT; CLOPIDOGREL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DACTINOMYCIN; DEXAMETHASONE; DNA; DOXORUBICIN; ETHYLENE VINYL ACETATE COPOLYMER; EVEROLIMUS; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; METAL; METHOTREXATE; MYCOPHENOLIC ACID; PACLITAXEL; QP 2; RAPAMYCIN; TACROLIMUS; UNINDEXED DRUG; VINBLASTINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLEEDING DISORDER; BLOOD VESSEL INJURY; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; CROHN DISEASE; DIABETES MELLITUS; DNA SYNTHESIS INHIBITION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG TISSUE LEVEL; ENZYME INHIBITION; HEART DEATH; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; MATERIAL COATING; META ANALYSIS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE THROMBOSIS; RESTENOSIS; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; SYSTEMATIC REVIEW; THROMBOCYTE AGGREGATION;

EID: 33845391349     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152906779010755     Document Type: Review

References (63)

1. Fischman, D.L., Leon, M.B., Baim, D.S., Schatz, R.A., Savage, M.P., Penn, I., Detre, K., Veltri L., Ricci, D. Stent Restenosis Study Investigators and M Nobuyoshi, A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med. 1994, 331, 496-501.
2. Eduardo Sousa, J., Serruys, P.W., Costa, M.A. Circulation 2003, 107, 2274.
3. Lovich, M.A., Creel, C., Hong, K., Hwang, C.W., Edelman, E.R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 2001, 90(9), 1324-1335.
4. Hwang, C.W., Wu, D., Edelman, E.R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001, 104, 600-605.
5. Van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., Van Beusekom, H.M., Serruys, P.W., Holmes, D.R. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94, 1690-1697.
6. Drachman, D.E., Edelman, E.R., Seifert, P., Groothuis, A.R., Bornstein, D.A., Kamath, K.R. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J. Am. Coll. Cardiol. 2000, 36, 2325-2332.
7. Suzuki, T., Kopia, G., Hayashi, S., Bailey, L.R., Llanos, G., Wilensky, R. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104(10), 1188-1193.
8. Lewis, A.L., Stratford, P.W. Phosphorylcholine-coated stents. J. Long Term Eff. Med. Implants. 2002, 12(4), 231-250.
9. Bartorelli, A.L., Trabattoni D., Fabbiocchi, F., Montorsi, P., De Martini, S., Calligaris, G., Teruzzi, G., Galli, S., Ravagnani P. Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J. Interv. Crdiol, 2003, 16, 499-505
10. Palmaz, J.C., Bailey, S., Marton, D., Sprague, E. Influence of stent design and material composition on procedure outcome. J. Vasc. Surg. 2002, 36(5), 1031-1039.
11. Tamai, H., Igaki, K., Kyo, E., Kosuga, K. Kawashima, A., Matsui, S. Initial and 6-month results of biodegradable poly-1-lactic acid coronary stents in humans. Circulation 2000, 102(4), 399-404.
12. Finkelstein, A., McClean, D., Kar, S., Takizawa, K., Varghese, K., Baek, N. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 2003, 107(5), 777-784.
13. Mohacsi, P.J., Tuller, D., Hulliger, B. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J. Heart Lung Transplant 1997, 16, 484-92.
14. Gallo, R., Padurean, A., Jayaraman, T. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999, 99, 2164-70.
15. Mekhail, T., Markman, M. Expert. Opin. Pharmacother. 2002, 3, 755-766.
16. Toru, Kataoka., Eberhard, Grübe., Yasuhiro, Honda., Yoshihiro, Morino., Seung-Ho, Hur., Bonneau, Heidi N., Carlo, Di Mario., Giulio, Guagliumi., Karl, E. 7-Hexanoyltaxol-Eluting Stent for Prevention of Neointimal Growth. Circulation 2002, 106, 1788.
17. Huang, Y., Salu, K., Liu, X, Li, S., Wang, L., Verbeken, E., Bosmans, J. Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. Heart 2004, 90, 195-199
18. Gobeil, F., Laflamme, M., Bouchard, M., Campbell, E., Wood, M., St-Jacques, P., Vincent, J., Leclerc, G. Biodivysio stent coated with metaloproteinase inhibitor reduces neointimal hyperplasia in a porcine coronary artery restenosis model. Circulation 2001, 104, 388.
19. De Scheerder, L., Wang, K., Wliczek, K, Van Dorpe, J., Verbeken, E., Desmet, W., Schacht, E., Piessens, J. Local methylprednisolone inhibition of foreign body response to coated intracoronary stents. Coron. Artery Dis.1996, 7, 161-166.
20. Fauci A.S., Dale, D.C., Balow, J.E. Glucocorticosteroid therapy: mechanism of action and clinical considerations. Ann. Intern. Med. 1976, 84, 304-314.
21. Lincoff, A.M., Furst, J.G., Ellis, S.G., Tuch, R.J., Topol, E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J. Am. Coll. Cardiol. 1997, 29, 808-816.
22. Lee, C.W., Chae, J.K., Lim, H.Y., Hong, M.K., Kim, J.J., Park, S.W., Park, S.J. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am. Heart J. 1999, 138, 60-63.
23. Villa, A.E., Guzman, L.A., Chen, W., Golomb, G., Levy, R.J., Topol, E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 1994, 93, 1243-1249.
24. Waksman, R. Drug-eluting stents from bench to bed. Cardiovasc. Radiat. Med. 2002, 3, 226-241
25. Kutryk, M.J., Foley, D.P., Van den Brand, M., Hamburger, J.N., Van der Giessen, W.J., DeFeyter, P.J., Bruining, N., Sabate, M., Serruys, P.W. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the Thoraxcenter of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. 2002, 39, 281-287.
26. Klugherz, B.D., Jones, P.L., Cui, X., Chen, W., Meneveau, N.F., DeFelice, S., Connolly, J., Wilensky, R.L., Levy, R.J. Gene delivery from a DNA controlled-release stent in porcine coronary arteries. Nat. Biotechnol. 2000, 18, 1181-1184.
27. Rogers, C., Edelman, E.R. Endovascular stent design dictates experimental restenosis and thrombosis. Circulation 1995, 91, 2995-3001.
28. Rogers, C.D.K. Drug eluting stents: role of stent design, delivery vehicle, and drug selection. Rev. Cardiovasc. Med. 2002, 3, S16-S22.
29. Hehrlein, C., Zimmermann, M., Metz, J., Ensinger, W., Kubler, W. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron. Artery Dis. 1995, 6, 581-586.
30. Garasic, J.M., Edelman, E.R., Squire, J.C., Seifert, P., Williams, M.S., Rogers, C. Stent and artery geometry determine intimal thickening independent of arterial injury. Circulation 2000, 101, 812-818.
31. Kastrati, A., Dirschinger, J., Boekstegers, P., Elezi, S., Schuhlen, H., Pache, J., Steinbeck, G., Schmitt, C., Ulm, K., Neumann, F.J., Schomig, A. Influence of stent design on 1-year outcome after coronary stent placement: a randomized comparison of 5 stent types in 1,147 unselected patients. Catheter Cardiovasc. Interv. 2000, 50, 290-297.
32. Whelan, D.M., Van der Giessen, W.J., Krabbendam, S.C., Van Vliet, E.A., Verdouw, P.D., Serruys, P.W., Van Beusekom, H.M. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000, 83, 338-345.
33. McKenna, C.J., Camrud, A.R., Sangiorgi, G., Kwon, H.M., Edwards, W.D., Holmes, D.R., Schwart, R-S. Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents. J. Am. Coll. Cardiol. 1998, 31, 1434-1438.
34. Van der Giessen, W.J., Lincoff, A.M., Schwartz, R.S., Van Beusekom, H.M., Serruys, P.W., Holmes, D.R., Ellis, S.G., Topol, E.J. Marked inflammatory sequelae to implantation of biodegradable and non-biodegradable polymers in porcine coronary arteries. Circulation 1996, 94, 1690-1697.
35. Tamai, H., Igaki, K., Kyo, E., Kosuga, K., Kawashima, A., Matsui, S., Komori, H., Tsuji, T., Motohara, S., Uehata, H. Initial and 6-month results of biodegradable polylactic acid coronary stents in humans. Circulation 2000, 102, 399-404.
36. Lee, S.H., Szimai, I, Carpenter, K. In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. Coron. Artery Dis. 2002, 13, 237-241.
37. Lewis, A.L., Tolhurst, L.A., Stratford, P.W. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002, 23, 1697-1706.
38. Klugherz, B.D., Llanos, G., Lieuallen, W. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron. Artery Dis. 2002, 13, 183-188.
39. Suzuki, T., Kopia, G., Hayashi, S. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104, 1188-1193.
40. Morice, M.C., Serruys, P.W., Sousa, J.E. Randomized study with the sirolimus-coated bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 2002, 346, 1773-1780.
41. Hiatt, B.L., Ikeno, F., Yeung, A.C., Carter, A.J. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc. Interv. 2002, 55, 409-417.
42. Heldman, A.W., Cheng, L., Jenkins, G.M. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001, 103, 2289-2295.
43. Sousa, J.E., Costa, M.A., Abizaid, A., Feres, F., Pinto, I.M., Seixas, A.C., Staico, R., Mattos, L.A., Sousa, A.G., Falotico, R., Jaeger, J., Popma, J.J., Serruys, P.W. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001, 103, 192-195.
44. Sousa, J.E., Costa, MA., Abizaid, A., Feres, F., Pinto, I.M., Seixas, A.C., Staico, R., Mattos, L.A., Sousa, A.G., Falotico, R., Jaeger, J., Popma, J.J., Serruys, P.W. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001, 104, 2007-2011.
45. Sousa, J.E., Costal, M.A., Abizaid, A.C., Seixas, Abizaid, A.C., Feres, A.S. F., Mattos, L.A., Falotico, R., Jaeger, J., Popma, J.J., Serruys, P.W. Two-year angiographic and intravascular ultrasound follow-up after implantation of Sirolimus-eluting stents in human coronary arteries. Circulation 2003, 107, 381-383.
46. Morice, M.C., Serruys, P.W., Sousa, J.E., Fajadet, J., Ban Hayashi, E., Perin, M., Colombo, A., Schuler, G., Barragan, P., Guagliumi, G., Molnar, F., Falotico, R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 2002, 346, 1773-1780
47. Curfman, G.D. Sirolirmus-eluting coronary stents. N. Engl. J. Med. 2002, 346, 1770-1771.
48. Serruys, P.W., Degertekin, M., Tanabe, K., Abizaid, A., Sousa, J.E., Colombo, A., Guagliumi, G., Wijns, W., Lindeboom, W.K., Ligthart J., De Feyter, P.J., Morice, M.C. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002, 106, 798-803
49. Schofer, J., Schluter, M., Gershlick, A.H., Wijns, W., Garcia, E., Schampaert, E., Breithardt, G. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003, 362, 1093-1099.
50. Grube, E., Buellesfeld, L. Everolimus for stent-based intracoronary applications. Rev. Cardiovasc. Med. 2004, 5, S3-8.
51. Chen, M.C., Liang, H.F., Chin, Y.L., Chang, Y., Wei, H.J., Sung, H.W. A novel drug-eluting sten spray-coated with multi-layers of collagen and sirolimus. J. Control. Releas 2005, 108, 178-189.
52. Pires, N.M., van der Hoeven, B.L., de Vries, M.R., Havekes, L.M., van Vlijmen, B.J., Hennink, W.E., Quax, P.H., Jukema, J.W. Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(ε-caprolactone) stent cuff. Biomaterials 2005, 26, 5386-5394.
53. Jaschke, B., Michaelis, C., Milz, S., Vogeser, M., Mund, T., Hengst, L., Kastrati, A., Schomig, A., Wessely, R. Local statin therapy differentially interferes with smooth muscle and endrithelial cell proliferation and reduces neointima on a drug-eluting stent platform Cardiovasc. Res. 2005, 68, 483-492.
54. Morice, M.C., Aubry, P., Benveniste, E., Bourdonnec, C., Commeau, P. The MUST trial: acute results and six-month clinical follow-up. J. Invasive Cardiol. 1998, 10(8), 457-463.
55. De Jaegere, P., Mudra, H., Figulla, H., Almagor, Y., Doucet, S., Penn I. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study). Eur. Heart J. 1998, 19(8), 1214-1223.
56. van der Hoeven, B.L., Pires, N.M., Warda, H.M., Oemrawsingh, P.V., van Vlijmen, B.J., Quax, P.H., Schalij, M.J., van der Wall, E.E., Jukema, J.M. Drug-eluting stents: results, promises and problems. Intern. J. Cardiol. 2005, 99, 9-17.
57. Willem, J., Van der Giessen, A., Michael, L., Schwartz, R.S., Van Beusekom, H.M., Serruys, P.W., Holmes, D.R. Jr., Ellis, S.G., Topol, E.J. Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. Circulation 1996, 94, 1690-1697.
58. Lemos, P.A., Saia, F., Ligthart, J.M., Arampatzis, C.A., Sianos, G., Tanabe, K. Coronary restenosis after sirolimus-eluting stent implantation. Morphological description and mechanistic analysis from a consecutive series of cases. Circulation 2003, 108, 257-260.
59. Colombo, A., Orlic,D., Stankovic, G., Corvaja, N., Spanos, V., Montorfano M. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 2003, 107(17), 2178-2180.
60. Orford, J.L., Lennon, R., Melby, S. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J. Am. Coll. Cardiol. 2002, 40, 1567-1572.
61. Virmani, R., Farb, A., Kolodgie, F.D. Histopathologic alterations after endovascular radiation and antiproliferative stents: similarities and differences. Herz 2002, 27, 1-6.
62. Babinska, A., Markell, M.S. Salifu, M.O., Akoad, M., Ehrlich, Y.H., Kornecki, E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol. Dial. Transplant 1998, 13, 3153-3159.
63. Lemos, P.A., Lee, C., Degertekin, M. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes Insight from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry. J. Am. Coll. Cardiol. 2003, 41, 2093-2099.